Clinical Trial Update: VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for VT-EBV-N in EBV-positive extranodal NK/T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma

Drugs mentioned

• VT-EBV-N

Snippet

Sponsor: ViGenCell Inc. | Conditions: Extranodal NK/T-cell Lymphoma | Phase 2 | Status: UNKNOWN